The identification and investigation of sentinel cases has illuminated genetic discrimination in the US. Its occurrence impedes applications of biotechnology and is a primary focus of public policy activity at the federal level. Continued research and informed responses may make genetic nondiscrimination more likely.
References
Billings, P. et al. Am. J. Hum. Genet. 50, 476–482 (1992).
Billings, P. Genet. Med. 2, 207–208 (2000).
Hook, E. Am. J. Hum. Genet. 51, 897–898 (1992).
Hudson, K.L., Rothenberg, K.H., Andrews, L.B., Kahn, M.J.E. & Collins, F.S. Science 270, 391–393 (1995).
Murray, T. et al. Genetic Information and Health Insurance: Report of the NIH/DOE Task Force on Genetic Information and Insurance (National Institutes of Health, Bethesda, 1993).
Lehrman, S. Nature 371, 468 (1994).
Testimony of John W. Rowe, M.D., Chairman and CEO, Aetna Inc. before the House Judiciary Subcommittee on the Constitution. 12 September 2002.
Norman-Bloodsaw v. Lawrence Berkeley Laboratory. 135 F.3d 1260, 9th Cir. 1998.
Szekely, P. Railroad to pay $2.2 million in DNA test case illegally testing workers for genetic defects. Reuters. 8 May 2002.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Billings, P. Genetic nondiscrimination. Nat Genet 37, 559–560 (2005). https://doi.org/10.1038/ng0605-559
Issue Date:
DOI: https://doi.org/10.1038/ng0605-559
- Springer Nature America, Inc.
This article is cited by
-
Genetic Counseling in the Adult with Congenital Heart Disease: What is the Role?
Current Cardiology Reports (2011)
-
How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing?
Clinical Pharmacology & Therapeutics (2009)
-
Beyond GINA
Nature Medicine (2008)
-
Three barriers to innovative diagnostics
Nature Biotechnology (2006)